Three RCTs [50–52], one exploratory trial [53], and one expert opinion report [54] were retrieved from the literature search to support the preference for TPO-RAs with low or very low risk of hepatic side effects in ITP patients with concomitant liver dysfunction. The gene discussed is TPO; the disease is Decreased liver function.